India · Delayed Price · Currency is INR Best Agrolife Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw revenue and profit declines due to adverse weather and high generic inventory, but patented products and operational improvements provided resilience. Management expects stabilization in FY26 and a return to growth and higher margins from FY27, with international expansion and new product launches as key drivers.
-
Q2 and H1 FY2026 saw revenue and margins decline due to adverse weather, but operational discipline, inventory reduction, and a shift to patented products improved resilience. Management guides for INR 1,500 crore turnover and 13%-14% EBITDA margin for FY2026, with a positive Rabi outlook.
-
Q1 FY26 saw a 25%-27% YoY revenue decline to INR 382 crore, but gross margin rose to 30% and EBITDA margin to 12% due to a focus on patented products and operational efficiency. FY26/27 revenue is guided at INR 1,600-1,700 crore with EBITDA margin above 15%.
Fiscal Year 2025
-
Q4 FY25 saw a strong turnaround with losses sharply reduced and gross margin up to 29.5%. Focus remains on branded, patented products, cost optimization, and cash flow, with INR 150 crore expected from new launches and EBITDA margin targeted at 15-18% for FY26.
-
Q3 FY2025 saw revenue and profitability decline due to adverse weather, lower institutional sales, and high sales returns, despite improved gross margins from branded products. Strategic partnerships, new patents, and cost optimization are expected to drive better performance in FY2026. FY2025 revenue guidance was revised downward, with Q4 expected to be better than last year.
-
Q2 and H1 FY25 saw improved margins and strong branded business growth, despite lower overall revenue due to a strategic shift from institutional sales. Guidance remains robust, with new patented products and brownfield expansion supporting future growth.
-
Q1 FY25 saw lower revenue and profit due to a strategic shift to branded products, high-cost inventory, and price competition, but branded sales now make up 63% of revenue. Management expects improved margins and growth in coming quarters as new patented products scale and inventory is liquidated.